UCB Biopharma SRL

Commercial

Meheni khellaf - Chief Investigator - UCB Biopharma SRL - Belgium HeadquartersMeheni khellaf - Corresponding Applicant - UCB Biopharma SRL - Belgium Headquarters - Collaborator -

CPRD473

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by “sticky” blood resulting in recurrent blood clots (thrombosis) or pregnancy complication. Nowadays, anticoagulants and blood thinners form the cornerstone of treatment, but a significant proportion of patients continue to experience thrombosis or pregnancy complication despite this treatment. In order to develop better treatments for APS, it is important to first understand the epidemiology of the disease including incidence and prevalence in the UK population.

The incidence and prevalence of antiphospholipid antibody syndrome (APS) is largely unknown. Duarte-Garcia (2019) has estimated for the population of Olmsted County, Minnesota, with the age- and sex-adjustment to the 2010 US white population: the overall annual incidence rate of adults aged ≥ 18 years was 2.1 (95% CI: 1.4-2.8) per 100,000, and the prevalence was 50 per (95% CI: 42-58) 100,000. Gomez-Puerta (2014) estimated the incidence as 5 cases per 100,000 person-years and prevalence of 40-50 cases per 100,000 persons. Given this lack of data we intend to estimate these rates in the population of UK by using the CPRD database over the period study 2010-2019. The target study population included persons in UK who are registered with a primary care practice included in the CPRD primary care databases (GOLD or Aurum)For practices permitting linkage to the HES datasets, sensitivity analysis will be undertaken to assess the robustness of incidence and prevalence estimates based on primary care records versus hospital; records.

30/03/2021

Release